by | Posted 4.10.2012 | Post Comment (No Comments)

About VIVUS, Inc. (VVUS)

VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes.

For more info: VIVUS Website, VIVUS Investor Relations

Recent Dividend Posts About VIVUS, Inc (VVUS)

Vivus: Ready To Gain From Qnexa@ Dividend Kings
-more coming soon


[stocks s=”VVUS”]